Endo launches unsolicited bid for Salix; withdraws offer
Endo International PLC launched an unsolicited proposal to acquire gastrointestinal specialist Salix Pharmaceuticals Ltd. for a combination of 1.4607 Endo common shares and $45.00 in cash per Salix share, which would value the deal at $11bn ($171.81 for each Salix share).
- Specialty Pharmaceuticals
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.